ASI’s collaboration with the CytoCell® division of OGT
We are thrilled to announce our collaboration with the CytoCell® division of OGT, a Sysmex Group company and a global leader in diagnostic genomic solutions! This partnership expands our global reach and adds value to customers in Cytogenetics laboratories.
Harnessing Augmented Intelligence: The New Paradigm in Digital Pathology
In “Harnessing Augmented Intelligence: The New Paradigm in Digital Pathology,” we explore how Augmented Intelligence is reshaping the field of digital pathology.
Enhancing Efficiency: The Rise of Automation in Digital Pathology
In the ever-evolving healthcare sector, the integration of automation in digital pathology stands out as a beacon of progress. This transformation is leading to faster diagnoses, reduced human errors, and heightened efficiency, revolutionizing traditional pathology workflows.
The role of karyotyping in a modern clinical laboratory of medical Cytogenetics|Cytogenomics
RNDr. Jiří Horáček will present the Cytogenetic Laboratory, its background and the range of methods in use. He will explain the reasons which led to the introduction of automatic scanning and karyotyping as well as the procedure of this implementation.
Streamlined Processes: The Value of Integrated Workflows in Pathology
The medical diagnostics field is seeing tangible changes with the rise of digital pathology. This isn’t just about new tools or technologies—it’s about a fundamental shift in approach.
Computer-aided quantitative analysis as second opinion in the assessment of low HER2 IHC score in breast cancer – a pilot evaluation
Computer-aided quantitative analysis as second opinion in the assessment of low HER2 IHC score in breast cancer – a pilot evaluation.
The Digital Shift: Current Landscape of Digital Pathology
In an ever-evolving digital age, even traditionally conservative fields like medicine aren’t exempt from transformation. Our blog delves into the current landscape of digital pathology, charting its journey from the conventional microscopes and glass slides to an interconnected, global ecosystem.
Validation of Applied Spectral Imaging for Ki-67
The Ki-67 index is critical in many malignancies’ grading that correlates to prognoses and therapeutics. However, the assessment is not standardized.
MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53/p53 – a Nordic Lymphoma Group study
The transcription factor MYC is a well-described oncogene with an important role in lymphomagenesis, but its significance for clinical outcome in mantle cell lymphoma (MCL) remains to be determined.
The significance of programed cell death-ligand 1 expression in vestibular schwannoma
Published studies report a difference in the PD-L1 positivity rate in malignant peripheral nerve sheath tumors. In this article, the authors examined PD-L1 expression and lymphocyte infiltration in patients with vestibular schwannoma.
Validation of MYC and BCL6 rapid break apart digital fluorescence in situ hybridization assays for clinical use
Detection of gene rearrangements in MYC and human B-cell lymphoma 6 using fluorescence in situ hybridization (FISH) are important in the evaluation of lymphomas, in particular diffuse large B-cell lymphoma and Burkitt lymphoma.
Feasibility and Toxicity of Interval-Compressed Chemotherapy in Asian Children and Young Adults with Sarcoma
The outcome of children and young adults with sarcoma has improved dramatically with the use of systemic chemotherapy in the context of multimodality treatment.